NEW YORK ( TheStreet) -- Achillion Pharmaceuticals (ACHN) was one of several stocks trading near $5 poised to move on above-average volume Wednesday after the company announced positive results for its hepatitis C drug.
Achillion Pharmaceuticals jumped nearly 20% in Tuesday's after-hours session after the company said Phase 1b clinical trial data showed its ACH-1625 treatment in third and fourth patient cohorts achieved "meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C."
Shares of Achillion closed Tuesday at $2.36 and rose to $2.81 in late trading. The 50-day average daily share volume for Achilion is 225,000, according to the Nasdaq.
Elsewhere, SMTC Corp. (SMTX) jumped by 55 cents, or 15.3%, to $4.15 in the premarket session after the electronics manufacturing services provider reported first-quarter earnings from continuing operations of 14 cents a share, compared with a year-ago loss of 6 cents a share. The 50-day average daily volume for SMTC is 379,000.China Wind Systems (CWS) was also poised to trade sharply higher Wednesday after the company said it anticipates full-year revenue in a range of $76.5 million to $85 million and earnings before interest, taxes, depreciation and amortization, or EBITDA, of $22.7 million to $25.2 million. That compares to 2009 revenue of $53.5 million and EBITDA of $11 million. China Wind Systems said it is now expects stronger sales of precision forged products used in large wind turbines in 2010. Shares closed Tuesday at $3.77 but rose nearly 18% in late trading. The three-month average daily volume for China Wind Systems is 80,000, according to Yahoo! Finance.
More on China
|Construction Craze: China Watch
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV